Literature DB >> 6971309

The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.

V C Carter, P A Schaffer, S S Tevethia.   

Abstract

The participation of herpes simplex virus (HSV) glycoproteins in T cell-mediated lysis of HSV-infected syngeneic target cells was examined by using a temperature sensitive (ts) mutant defective in glycoprotein synthesis at the nonpermissive temperature (39 degrees C), and 2-deoxy-D-glucose and tunicamycin, known inhibitors of both HSV replication and glycoprotein synthesis in HSV-infected cells. Lymphocytes cytotoxic for HSV-infected cells lysed C57BL/6 Wt-3 cells infected with the mutant, ts A1, at 39 degrees C less efficiently than at 33 degrees C. Treatment of HSV-infected C57BL/6 Wt-3 cells with 1% 2-deoxy-D-glucose for 14 hr reduced their susceptibility to T cell-mediated lysis by 73% in the 51Cr release assay. Treatment of HSV-infected C57BL/6 Wt-3 cells with 0.2 microgram/ml tunicamycin for 14 hr reduced their susceptibility to T cell-mediated lysis by 78% in the 51Cr release assay. The reduction in T cell-mediated lysis by 2 deoxy-D-glucose and tunicamycin was found not to be due to the effects of the compounds on the H-2 antigens. We conclude that HSV specific glycoproteins are involved in T cell-mediated lysis of HSV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6971309

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.

Authors:  S D Marlin; S L Highlander; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

2.  Kinetics of expression of herpes simplex virus type 1-specific glycoprotein species on the surfaces of infected murine, simian, and human cells: flow cytometric analysis.

Authors:  S R Jennings; P A Lippe; K J Pauza; P G Spear; L Pereira; S S Tevethia
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

3.  Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites.

Authors:  S D Marlin; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

4.  Cloned bovine cytolytic T cells recognize bovine herpes virus-1 in a genetically restricted, antigen-specific manner.

Authors:  G A Splitter; L Eskra; A F Abruzzini
Journal:  Immunology       Date:  1988-01       Impact factor: 7.397

5.  Monoclonal antibodies suppress replication of herpes simplex virus type 1 in trigeminal ganglia.

Authors:  J E Oakes; R N Lausch
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

6.  Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice.

Authors:  P M Smith; Y Zhang; S R Jennings; D J O'Callaghan
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Mapping of a herpes simplex virus type 2-encoded function that affects the susceptibility of herpes simplex virus-infected target cells to lysis by herpes simplex virus-specific cytotoxic T lymphocytes.

Authors:  V C Carter; S R Jennings; P L Rice; S S Tevethia
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

8.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

9.  Murine cellular cytotoxicity to syngeneic and xenogeneic herpes simplex virus-infected cells.

Authors:  S Kohl; D B Drath; L S Loo
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

10.  A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.

Authors:  C A O'Donnell; W L Chan
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.